Read our Recent Headlines


June 25 Biotech Update

So that was unexpected. First, the market is down and sector is higher. Second, we got another large merger to digest. Obviously I will focus on the deal and its.

June 24 Market Update

The sector is in an interesting spot. Tensions with Iran remain elevated but did not escalate, which should lead to a risk on move and while the market was tepidly.

June 20th Biotech Update

The sector continues to do well but we may have some additional macro coming with the Iran downing of an American drone in international waters. The market does not seem.

June 18th Biotech Update

We got a very nice follow through during the day yesterday for the sector. That is exactly what you wanted to see and ideally it continues for the next couple.

June 17 Biotech Update

It is a good start to the week with merger Monday coming back the sector albeit with names we were not expecting. The XBI has been in a nice tight.

June 14 Biotech Update

It is Friday again, so be on the lookout for those rumors or late day runners. A slow start to the morning in terms of price action but we are.

June 13 Biotech Update

I am back but honestly we are entering the summer quite period with little news to drive the sector higher or lower. We did get a break from the macro,.

Introduction


Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!